Sponsors and stakeholders soon could see more new US Food and Drug Administration guidances that skip the public comment process prior to their finalization in an effort to speed publication of agency thinking.
US FDA Considers Making More Guidance Final Without Public Comment
Increased use of the ‘immediate implementation’ provision in the agency’s Good Guidance Practices could help reduce stakeholder uncertainty.
